Abstract:Multidrug-resistant Gram-negative bacterial infections are exponentially increasing, posing one of the most urgent global healthcare and economic threats. Due to the lack of new therapies, the World Health Organization classified these bacterial species as priority pathogens in 2017, known as ESKAPE pathogens. This classification emphasizes the need for urgent research and development of novel targeted therapies. The majority of these priority pathogens are Gram-negative species, which possess a structurally dynamic cell envelope enabling them to resist multiple antibiotics, thereby leading to increased mortality rates. Despite 6 years having passed since the WHO classification, the progress in generating new treatment ideas has not been sufficient, and antimicrobial resistance continues to escalate, acting as a global ticking time bomb. Numerous efforts and strategies have been employed to combat the rising levels of antibiotic resistance by targeting specific resistance mechanisms. These mechanisms include antibiotic inactivating/modifying enzymes, outer membrane porin remodelling, enhanced efflux pump action, and alteration of antibiotic target sites. Some strategies have demonstrated clinical promise, such as the utilization of beta-lactamase inhibitors as antibiotic adjuvants, as well as recent advancements in machine-based learning employing artificial intelligence to facilitate the production of novel narrow-spectrum antibiotics. However, further research into an enhanced understanding of the precise mechanisms by which antibiotic resistance occurs, specifically tailored to each bacterial species, could pave the way for exploring narrow-spectrum targeted therapies. This review aims to introduce the key features of Gram-negative bacteria and their current treatment approaches, summarizing the major antibiotic resistance mechanisms with a focus on Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Additionally, potential directions for alternative therapies will be discussed, along with their relative modes of action, providing a future perspective and insight into the discipline of antimicrobial resistance.

Respiratory tract infections: an update on the complexity of bacterial diversity, therapeutic interventions and breakthroughs

Introduction: Evolving needs in respiratory tract infections

Therapeutic Antibodies for the Treatment of Respiratory Tract Infections—Current Overview and Perspectives

The past decade in bench research into pulmonary infectious diseases: What do clinicians need to know?

Antimicrobials: An update on new strategies to diversify treatment for bacterial infections

[Bacterial resistance and antimicrobial therapy in respiratory medicine and intensive care]

Antimicrobial resistance: a concise update

Resistance of Gram-Positive Bacteria to Current Antibacterial Agents and Overcoming Approaches

An escape from ESKAPE pathogens: A comprehensive review on current and emerging therapeutics against antibiotic resistance

ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics

Critical insights from recent outbreaks of Mycoplasma pneumoniae: decoding the challenges and effective interventions strategies

Microbiome Modulation as a Novel Strategy to Treat and Prevent Respiratory Infections

Antimicrobial molecules in the lung: formulation challenges and future directions for innovation

Pneumococcal resistance: the treatment challenge

Respiratory Tract Infections and Laboratory Diagnostic Methods: A Review with A Focus on Syndromic Panel-Based Assays

An Update on Recent Clinical Trial Data in Bloodstream Infection

Recent perspectives on the virulent factors and treatment options for multidrug-resistant Acinetobacter baumannii

New tools to mitigate drug resistance in Enterobacteriaceae – Escherichia coli and Klebsiella pneumoniae

The threat of multidrug-resistant/extensively drug-resistant Gram-negative respiratory infections: another pandemic

Evaluation of Antibiotic Resistance Mechanisms in Gram-Negative Bacteria

Antibiotic resistance in chronic respiratory diseases: from susceptibility testing to the resistome